2023
Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study
Sorial M, Koh M, Boussi L, Han J, Peng L, Eche-Ugwu I, Duan R, Lei M, Miranda E, Chiattone C, Stuver R, Horwitz S, Turizo M, McCabe S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Jain H, Sengar M, Eipe T, Shet T, Singh S, Lou U, Raghib H, Gabler J, Koh M, Van Der Weyden C, Prince M, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Federico M, O'Connor O, Cabrera M, Marchi E, Shen C, Shah D, Jain S. Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study. Blood 2023, 142: 3080. DOI: 10.1182/blood-2023-182341.Peer-Reviewed Original ResearchNK-cell neoplasmsTherapy sequenceCohort studyMost patientsSurvival outcomesPatient cohortCox modelAnaplastic large cell lymphomaFirst lineAllogeneic hematopoietic transplantOptimal therapy sequencePTCL-NOS patientsRetrospective cohort studyKaplan-Meier curvesLarge cell lymphomaEpigenetic modifiersImmunomodulatory imide drugsPI3K inhibitorsAntibody-drug conjugatesAllogeneic HSCTCommon histologyPlanned subgroupPrimary refractoryAutologous HSCTHazard ratio
2011
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCase-Control StudiesConnecticutCytokinesDisease-Free SurvivalFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateLymphoma, Non-HodgkinMiddle AgedModels, GeneticPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSocioeconomic FactorsSurvival AnalysisSurvivorsYoung AdultConceptsNon-Hodgkin lymphomaNHL survivalHazard ratioCytokine genesNon-Hodgkin lymphoma survivalCox proportional hazards modelIncident NHL casesConnecticut Tumor RegistryDisease-free survivalKaplan-Meier curvesRisk of deathProportional hazards modelCombination of polymorphismsImmune function genesIL6 genotypeNHL prognosisTumor RegistryHistologic typeTumor characteristicsDecreased riskSecondary cancersNHL casesTumor interactionCancer occurrenceLymphoma survival
2009
Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival. American Journal Of Hematology 2009, 85: 51-56. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overArylamine N-AcetyltransferaseConnecticutCytochrome P-450 CYP2E1FemaleFollow-Up StudiesGenotypeGlutathione S-Transferase piGlutathione TransferaseHumansIsoenzymesKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMiddle AgedPolymorphism, Single NucleotideProportional Hazards ModelsRegistriesYoung AdultConceptsNHL survivalHazard ratioLymphoma survivalChronic lymphocytic leukemia/small lymphocytic lymphomaNon-Hodgkin lymphoma survivalCox proportional hazards modelConnecticut Tumor RegistryKaplan-Meier curvesGenetic polymorphismsSmall lymphocytic lymphomaProportional hazards modelGlutathione S-transferaseCytochrome P450NHL prognosisN-acetyltransferasesTumor RegistryTumor characteristicsIncident casesLymphocytic lymphomaMetabolic pathwaysHazards modelSurvival analysisDrug metabolismEnvironmental carcinogensSurvival